Traws Pharma (NASDAQ:TRAW) Shares Down 3.5% – Time to Sell?

Traws Pharma, Inc. (NASDAQ:TRAW) shares were down 3.5% during mid-day trading on Tuesday . The company traded as low as $1.0514 and last traded at $1.09. Approximately 137,511 shares traded hands during trading, a decline of 66% from the average daily volume of 399,087 shares. The stock had previously closed at $1.13.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on TRAW shares. Zacks Research raised shares of Traws Pharma to a “hold” rating in a report on Thursday, December 4th. Weiss Ratings restated a “sell (e+)” rating on shares of Traws Pharma in a research note on Monday, December 22nd. Wall Street Zen lowered Traws Pharma from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Finally, HC Wainwright assumed coverage on Traws Pharma in a report on Wednesday, December 3rd. They issued a “buy” rating and a $8.00 price target for the company. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $8.00.

Traws Pharma Price Performance

The company has a fifty day moving average of $2.11 and a two-hundred day moving average of $1.90. The stock has a market capitalization of $8.71 million, a P/E ratio of 0.01 and a beta of 1.74.

Traws Pharma (NASDAQ:TRAW) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($9.16) by $8.82. Traws Pharma had a negative return on equity of 2,883.04% and a net margin of 3,028.25%.

Institutional Investors Weigh In On Traws Pharma

Several institutional investors and hedge funds have recently bought and sold shares of TRAW. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Traws Pharma during the 1st quarter worth approximately $759,000. Vestal Point Capital LP grew its stake in Traws Pharma by 133.3% during the 1st quarter. Vestal Point Capital LP now owns 175,000 shares of the company’s stock worth $402,000 after buying an additional 100,000 shares during the last quarter. Finally, Two Sigma Investments LP increased its position in Traws Pharma by 37.1% in the third quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock worth $41,000 after buying an additional 5,955 shares during the period. Institutional investors and hedge funds own 7.95% of the company’s stock.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.